Avet Pharmaceuticals

Avet Pharmaceuticals Inc. develops, manufactures, markets, and sells a broad portfolio of over 150 FDA-approved generic drugs in the United States across oral solids/liquids and injectables. The company covers multiple therapeutic areas such as cardiovascular disease, oncology, metabolic disease (including diabetes), infectious disease/anti-infectives, infusion therapy products for hospitals/clinics, pain management medications as well as some legacy branded products. Their business model focuses on both high-volume established generics and niche/high-barrier-to-entry products with limited competition. Recent years have included legal settlements related to industry-wide antitrust litigation but the company remains active with ongoing product launches.